Key Events This Week
2 Feb: Stock hits 52-week low at Rs.1,107.10
3 Feb: Significant gap up opening at Rs.1,163.65 (+5.11%)
6 Feb: Intraday high surge of 7.49%, closing at Rs.1,339.30 (+14.71%)
Weekly Close: Rs.1,339.30, +14.02% vs Sensex +1.51%
Feb 06
BSE+NSE Vol: 40.01 lacs
2 Feb: Stock hits 52-week low at Rs.1,107.10
3 Feb: Significant gap up opening at Rs.1,163.65 (+5.11%)
6 Feb: Intraday high surge of 7.49%, closing at Rs.1,339.30 (+14.71%)
Weekly Close: Rs.1,339.30, +14.02% vs Sensex +1.51%

Concord Biotech Ltd recorded a robust intraday performance on 6 Feb 2026, surging to a day’s high of Rs 1,264.8, marking an 8.32% increase from its previous close. The stock outperformed its sector and the broader market, reflecting notable trading momentum despite a subdued Sensex session.
Read full news article
Concord Biotech Ltd commenced trading with a significant gap up of 5.92% on 3 February 2026, signalling a robust start amid positive market sentiment in the Pharmaceuticals & Biotechnology sector. This upward opening follows a three-day decline, marking a notable reversal in the stock’s recent trend.
Read full news article
Concord Biotech Ltd’s shares touched a fresh 52-week low of Rs.1121 today, marking a significant decline amid a broader market recovery. The stock has underperformed its sector and benchmark indices, reflecting ongoing pressures on its financial performance and valuation metrics.
Read full news article
Concord Biotech Ltd’s stock price declined to a fresh 52-week low of Rs.1157 today, marking a significant milestone in its ongoing downward trajectory. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a combination of subdued financial performance and broader market dynamics.
Read full news article
Concord Biotech Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 October 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 January 2026, providing investors with the latest insights into its performance and outlook.
Read full news article
Concord Biotech Ltd’s shares declined to a fresh 52-week low of Rs.1159 on 30 Jan 2026, marking a significant drop amid sustained underperformance relative to its sector and benchmark indices. The stock’s latest intraday low represents a near 53% fall from its 52-week high of Rs.2451.65, reflecting ongoing pressures on the company’s financial metrics and market sentiment.
Read full news article
Concord Biotech Ltd’s stock declined sharply to a fresh 52-week low of Rs.1175.65 today, marking a significant downturn as the pharmaceutical and biotechnology company continues to face headwinds. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on its financial performance and valuation metrics.
Read full news article
Concord Biotech Ltd’s stock declined sharply to a fresh 52-week low of Rs.1175.65 on 28 Jan 2026, marking a significant downturn amid a sustained period of underperformance relative to its sector and broader market indices.
Read full news articlePursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended from time to time read with Para A of Schedule III thereto We wish to inform you that the Company has arranged Earnings Call with Investor/Analyst (Participants) to discuss the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and Nine months ended 31 December 2025 scheduled on Thursday 12th February 2026 at 03:30 P.M. IST. The Earnings Call invite is enclosed for your records.
Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 inter alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and nine months period ended 31 December 2025.
Enclosed herewith the certificate under Regulation 74(5) of the SEBI (DP) Regulations2018 for the quarter ended 31.12.2025
No Upcoming Board Meetings
Concord Biotech Ltd has declared 1070% dividend, ex-date: 03 Sep 25
No Splits history available
No Bonus history available
No Rights history available